Annals of Oncology 14:564-569, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer
1 Department of Radiation and Cellular Oncology and 2 Section of Hematology/Oncology, The University of Chicago, Chicago, IL; 3 Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston, TX; 4 Department of Radiation Oncology, Northwestern University, Chicago, IL, USA
Received 19 April 2002; revised 18 November 2002; accepted 3 December 2002
Background:
Since 1990, we have treated patients with advanced nasopharyngeal cancer with induction chemotherapy and concomitant chemoradiotherapy. We herein report the results of our experience.
Patients and methods:
From 1990 to 1999, 27 patients with locoregionally advanced nasopharyngeal cancer were treated with induction chemotherapy followed by concomitant chemoradiotherapy. Using the American Joint Committee on Cancer’s 1992 stage classification, all patients were stage III (11%) or IV (89%). By histology, 63% were poorly differentiated carcinoma and 37% squamous cell carcinoma. The median age was 42 years. Three cycles of induction chemotherapy consisting of cisplatin, 5-fluorouracil, leucovorin and interferon-
2b were administered, followed by concomitant chemoradiotherapy consisting of seven cycles of 5-fluorouracil, hydroxyurea and once-daily radiotherapy (FHX) on a week-on week-off schedule. The median radiotherapy dose was 70 Gy.
Results:
Clinical response to induction chemotherapy was 100%, 54.2% complete response (CR) and 45.8% partial response. Clinical and/or pathological (37% of all patients had post-treatment biopsy with or without neck dissection) CR after FHX was 100%. At a median follow-up of 52 months, three failures were observed. Two patients have died of disease, one of local failure and one of distant metastases. One patient is alive with an isolated rib metastasis. At 5 years, actuarial locoregional control is 93% and actuarial distant control 92%. The overall survival at 3 and 5 years is 88% and 77%, respectively. Four patients died of unrelated illnesses and had no evidence of disease with respect to their nasopharyngeal cancer. The progression-free survival at 3 and 5 years is 92% and 86%, respectively. Thirty-three per cent of patients required a reduction in the chemotherapy dose due to acute toxicity. Chronic toxicity was not observed, with all patients able to eat orally without dietary restrictions.
Conclusions:
Treatment of locoregionally advanced nasopharyngeal cancer with induction chemotherapy followed by concomitant chemoradiotherapy resulted in excellent overall survival with acceptable toxicity. These results are encouraging and warrant further investigation of intensified approaches.
Key words: concomitant chemoradiation therapy, induction chemotherapy, nasopharyngeal cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. P. Hui, B. B. Ma, S. F. Leung, A. D. King, F. Mo, M. K. Kam, B. K. Yu, S. K. Chiu, W. H. Kwan, R. Ho, et al. Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., January 10, 2009; 27(2): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. C. Wong, R. A. Soo, J. J. Lu, K. S. Loh, K. S. Tan, W. S. Hsieh, T. P. Shakespeare, E. T. Chua, H. L. Lim, and B. C. Goh Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma Ann. Onc., July 1, 2006; 17(7): 1152 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. C. Chan, S. F. Leung, R. K. C. Ngan, P. M. L. Teo, W. H. Lau, W. H. Kwan, E. P. Hui, H. Y. Yiu, W. Yeo, F. Y. Cheung, et al. Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma J Natl Cancer Inst, April 6, 2005; 97(7): 536 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-C. Yen, J. T.-C. Chang, S.-H. Ng, Y.-C. Chang, S.-C. Chan, K.-J. Lin, W.-J. Lin, Y.-K. Fu, and C.-Y. Lin The Value of 18F-FDG PET in the Detection of Stage M0 Carcinoma of the Nasopharynx J. Nucl. Med., March 1, 2005; 46(3): 405 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T.C. Chan, B. B.Y. Ma, Y.M. D. Lo, S.F. Leung, W.H. Kwan, E. P. Hui, T. S.K. Mok, M. Kam, L. S. Chan, S. K.W. Chiu, et al. Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA J. Clin. Oncol., August 1, 2004; 22(15): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ozyar and M. Cengiz With regard to "Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer" by Oh et al. (AnnOnc 2003; 14: 564-569) Ann. Onc., April 1, 2004; 15(4): 689 - 689. [Full Text] [PDF]
|
|
|
|
|
|
L. Licitra Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation? Ann. Onc., April 1, 2003; 14(4): 508 - 509. [Full Text] [PDF]
|
|